Ginkgetin induces apoptosis in 786-O cell line via suppression of JAK2-STAT3 pathway

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Renal cell carcinoma (RCC) exhibits resistance to conventional chemotherapy.
• Ginkgetin demonstrates efficacy against various carcinoma cells, but its role in RCC is largely unexplored.
• The Janus kinase 2 (JAK2)-Signal transducer and activator of transcription 3 (STAT3) pathway is implicated in cancer progression.

Purpose of the Study:

• To investigate the potential anticancer effects of Ginkgetin on renal cell carcinoma (RCC) using the 786-O cell line.
• To elucidate the mechanism underlying Ginkgetin's action, focusing on apoptosis induction and the JAK2/STAT3 signaling pathway.

Main Methods:

• Cytotoxic effects of Ginkgetin on 786-O cells were assessed using MTT assays over 24–72 hours.
• Apoptosis was quantified using an FITC Annexin apoptosis detection kit.
• Protein expression levels, including JAK2 and phosphorylated-STAT3, were analyzed via Western blotting. STAT3 activity was manipulated using interleukin-6 (IL-6) and small interfering RNA (siRNA).

Main Results:

• Ginkgetin demonstrated dose- and time-dependent suppression of 786-O cell growth, with an IC50 of 7.23 μM.
• Ginkgetin treatment led to increased apoptosis, evidenced by elevated caspase-8, caspase-9, and caspase-3 levels.
• Ginkgetin significantly reduced JAK2 and phosphorylated-STAT3 levels, irrespective of IL-6 pretreatment. siRNA-mediated STAT3 inhibition further enhanced Ginkgetin's growth-inhibitory effects.

Conclusions:

• Ginkgetin exhibits significant inhibitory effects on the proliferation of 786-O cells, likely mediated through the suppression of the JAK2/STAT3 pathway.
• These findings highlight Ginkgetin as a potential therapeutic agent for renal cell carcinoma.